ANEB
NASDAQ
US
Anebulo Pharmaceuticals, Inc. - Common Stock
$0.75
▼ $-0.23
(-23.47%)
Vol 6K
3
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$41.5M
ROE
-80.8%
D/E
0.00
Beta
-0.91
52W
$1–$3
Wall Street Consensus
6 analysts · Apr 20260
Strong Buy
0
Buy
3
Hold
1
Sell
2
Strong Sell
0.0%
Buy Rating
Price Chart
Similar Stocks
Earnings
Beat rate: 100.0%
Next Report
May 11, 2026
EPS Estimate: $-0.14
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Sep 2026 | $-0.14 | — | — |
| Dec 2025 | $-0.13 | $-0.05 | +$0.08 |
| Sep 2025 | $-0.12 | $-0.05 | +$0.07 |
| Jun 2025 | $-0.08 | $-0.05 | +$0.03 |
Quarterly Revenue & Earnings
| Quarter | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | -$2.5M | -$1.7M | -$2.1M | -$2.2M | -$2.0M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -80.8% | -90.1% | -90.1% | -80.8% | -80.8% | -80.8% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 24.53 | 25.29 | 25.29 | 24.53 | 24.53 | 24.53 |
Key Ratios
ROA (TTM)
-76.3%
P/B
5.1
EPS (TTM)
$-0.27
CF/Share
$-0.36
52W High
$3.42
52W Low
$0.90
$0.90
52-Week Range
$3.42
Financial Health
Free Cash Flow
-$1.3M
Cash
$9.0M
As of Dec 31, 2025
How does ANEB compare to Pharmaceuticals peers?
Peer group: Micro-cap Pharmaceuticals (All) · 171 companies
ANEB valuation vs Pharmaceuticals peers
P/E ratio
—
▼
0%
below
peers
(22.4)
vs Peers
vs Industry
Undervalued
P/S ratio
—
▼
0%
below
peers
(5.0)
vs Peers
vs Industry
Overvalued
P/B ratio
5.1
▲
139%
above
peers
(2.1)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(2.0%)
vs Peers
vs Industry
Low yield
ANEB profitability vs Pharmaceuticals peers
ROE
-80.8%
▼
49%
below
peers
(-54.3%)
vs Peers
vs Industry
Weak
Net margin
—
▼
0%
below
peers
(-47.4%)
vs Peers
vs Industry
Top tier
Gross margin
—
▼
0%
below
peers
(68.3%)
vs Peers
vs Industry
In line
ROA
-76.3%
▼
104%
below
peers
(-37.4%)
vs Peers
vs Industry
Weak
ANEB financial health vs Pharmaceuticals peers
D/E ratio
0.0
▼
100%
below
peers
(1.5)
vs Peers
vs Industry
Low debt
Current ratio
24.5
▲
630%
above
peers
(3.4)
vs Peers
vs Industry
Strong liquidity
Beta
-0.9
▼
197%
below
peers
(0.9)
vs Peers
vs Industry
More volatile
ANEB fundamentals radar
ANEB
Peer median
Industry
ANEB profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
ANEB vs peers: key metrics
Top Holders
Top 5: 53.6%22NW, LP
37.92%
$13.7M
Nantahala Capital Managemen…
7.44%
$2.7M
Mangrove Partners IM, LLC
6.19%
$2.2M
Vanguard Group Inc
1.07%
$387K
Morgan Stanley
0.98%
$354K
As of Dec 31, 2025
Latest News
No related news yet